Tilray Brands Reports Second Quarter Fiscal Year 2023 Financial Results

Rhea-AI Summary

Tilray reported financial results for Q2 ended November 30, 2022, highlighting a net revenue of $144.1 million, with a free cash flow of $25.4 million and operating cash flow of $29.2 million. The company maintained its leading market share in Canada at 8.3%. Despite facing industry challenges, Tilray achieved adjusted EBITDA of $11.7 million for the 15th consecutive quarter. Notably, Tilray completed the acquisition of Montauk Brewing Company, contributing to a 56% increase in beverage-alcohol sales to $21.4 million year-over-year.

Positive

• Achieved $29.2 million in operating cash flow.
• Maintained 8.3% market share in Canada.
• Beverage-alcohol sales increased 56% to $21.4 million.
• Gross profit rose 22% to $40.1 million.
• Cannabis gross profit increased 37% to $18.6 million.

Negative

• EPS reported at -0.11 and adjusted EPS at -0.06.

Achieved $29.2 Million of Operating Cash Flow and $25.4 Million of Free Cash Flow

15^th Consecutive Quarter of Positive Adjusted EBITDA

Maintains Leading Market Share Position in Recreational Cannabis in Canada and Medical Cannabis Across Europe

Net Revenue of $144.1 Million, On a Constant Currency Basis $157.6 million

EPS of -$0.11 and Adjusted EPS of -$0.06

Strategy in Place to Build the World’s Leading and Most Diversified Cannabis Lifestyle Consumer Packaged Goods Company

Completes Acquisition of Montauk Brewing Company, #1 Craft Beer in Metro New York

LEAMINGTON, Ontario and NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today reported financial results for the second fiscal quarter ended November 30, 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

Financial Highlights

• Strong financial position with $433.5 million in cash and marketable securities.
  
• Maintained #1 leadership position in Canada with 8.3% cannabis market share.
• Beverage-alcohol sales increased 56% to $21.4 million, over the prior year quarter, including revenue from acquisitions.
• Gross profit rose to $40.1 million, a 22% increase, year over year. Adjusted gross margin held at 29% compared to the year ago quarter.
• Cannabis gross profit increased 37% to $18.6 million from $13.5 million in the prior year quarter, while the gross margin percentage increased to 37% from 23%. This was driven by our success in implementing numerous cost-savings programs, offset in part by our allocated overhead from intentionally reducing production, coupled with the revenue realized from our strategic alliance with HEXO in the current year and in inventory provision in the prior year.
• Achieved $119.6 million in annualized cash cost-savings since the closing of the Tilray-Aphria transaction in May 2021, up from $108 million as of August 31, 2022.
• Adjusted EBITDA of $11.7 million, marking the 15^th consecutive quarter of positive adjusted EBITDA.
  

Irwin D. Simon, Tilray Brands’ Chairman and Chief Executive Officer, stated, “During the second quarter, Tilray Brands took decisive, effective actions to manage operating cash flow and focus the business on accretive acquisitions and a path to long term profitability. And we have certainly done so – even amid an evolving retail environment - by removing costs and driving efficiencies across the platform in supply chain, procurement, packaging, and labor. We are close to achieving our increased annualized cost savings target of $130 million, consistent with our commitment to building a lean, efficient, and dynamic business that will realize tangible and immediate benefits as the market improves.”

Mr. Simon continued, “Tilray Brands’ re-positioning as a global diversified portfolio of brands will drive our ability to seize top-line opportunities across geographies and business lines. In the U.S., this includes investing in, acquiring or building compelling and profitable lifestyle CPG brands across craft beverage-alcohol and wellness consumer products that are cannabis adjacent, resonate powerfully with consumers, and are strongly positioned in key markets. In Europe, we believe that we are extremely well-positioned overall in a cannabis market. And, in Canada, we will be patient and strategic in building our competitive positioning amid the price compression and difficult operating conditions that we expect will, inevitably, consolidate the oversupply of licensed producers. These efforts will be supported and enhanced by one of the strongest balance sheets in the industry with close to $433.5 million in cash and marketable securities on-hand.”

Operating Highlights

Maintained #1 Market Share Leadership in Canada; Positioned for Long-Term Growth in the Market – Against the backdrop of challenging cannabis market operating conditions, Tilray was able to maintain its top market share position due to the strength of its sought-after brands and products. This reflects the strength of the Company’s product innovation, including with respect to both strains and potencies. Looking ahead, Tilray’s focus on using data and consumer insights coupled with ongoing budtender and consumer education is expected to enable the acceleration of both sales and market share growth.

Well-Positioned to Capitalize on Growing Acceptance and Legalization of Cannabis across Europe – Even as Europe contends with a difficult economic climate that has negatively impacted the cannabis industry, the positive trends towards greater acceptance of medical cannabis and legalization of adult-use continue. We believe we are exceptionally well situated to benefit from the meaningful economic growth that will come to our industry as a result of these positive changes, given our ability to provide the most sought-after, consistent and sustainable cannabis products for the medical and adult-use markets. In Germany, we are in a win-win position regardless of whether in-country cultivation is exclusively permitted or whether imports are also allowed given our domestic footprint with our Aphria RX facility located in Germany along with our facility in Portugal. In addition to our supply-chain footprint, we are also uniquely positioned to take advantage of the insights and learnings we have developed through our participation in the Canadian adult-use market. This experience, paired with our competitively advantaged supply-chain footprint, gives us great confidence in our ability to lead the European medical market and German adult-use market in the future.

Continuing to Expand U.S. CPG and Craft-Beverage Portfolio, with Accretive Acquisition of Montauk Brewing Company – In the U.S., Tilray’s businesses include SweetWater Brewing Company, the 10th largest craft brewer in the nation; Breckenridge Distillery; and Manitoba Harvest, a pioneer in hemp, CBD and wellness products; as well as Montauk Brewing Company, the fastest growing craft beer brand and #1 craft brewer in Metro New York, which Tilray Brands acquired in the second quarter of fiscal 2023. The Montauk Brewing transaction was immediately accretive to EBITDA and the Company expects it will deliver strong revenue and adjusted EBITDA on a go-forward basis. This will be accomplished as a result of Tilray’s ability to leverage SweetWater’s excess capacity as well as its nationwide infrastructure to significantly expand Montauk Brewing’s distribution network beyond its concentrated presence in the Northeast, making it a true national brand.

The Company is focused on driving revenue gains across its diverse portfolio of businesses, which we believe will ultimately create a strong channel for additional revenue in adult-use cannabis, pending federal legalization.

Strategic Growth Actions

• September 2022 - Good Supply Launches New High-Potency Product Drop and Unveils Exclusive Orange Frost Live Resin
• September 2022 - Breckenridge Distillery Announces Nationwide Alignment and Renewed Distribution Agreement with Republic National Distributing Company
• September 2022 - RIFF Cannabis Brand Launches New ‘Drumsticks’ Product
• September 2022 - Tilray Medical Receives Approval to Extend Market Authorization in Italy
• September 2022 - SweetWater Brewing Company Unveils New Fall Craft-Beer Releases
• October 2022 - Tilray Medical Relaunches Cannabis Oral Solution Across Ireland
• October 2022 - Broken Coast Ranks #1 at the Budtender’s Association Collector’s Cup
• October 2022 - Green Flash Launches New Beers Across the U.S. and Unveils Refreshed Branding
• October 2022 - Breckenridge Distillery Announces Ultimate Whiskey and Beer Collaboration with Breckenridge Brewery
• October 2022 - Good Supply Cannabis Brand Reveals New Fall Flower Launches and Expands Distribution of Bestselling High-Potency Products
• November 2022 - Tilray Brands and Charlotte's Web Announce Strategic Alliance in Canada
• November 2022 - Leading Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Tilray Stockholders Vote “FOR” Tilray’s Proposal to Protect Stockholders and Promote Accountability
• November 2022 - Tilray Brands Acquires Montauk Brewing Company
• November 2022 - ‘Potently Canadian’ Cannabis Brand, CANACA, Launches New Products And #FeelTheBoost Campaign
• November 2022 - Tilray Launches ‘Take Back Control’ Platform to Provide Women with Free Medical Cannabis Resources
• December 2022 - Good Supply Cannabis Brand Launches ‘Peppermint Phatty’
• December 2022 - RIFF Cannabis Brand Launches New Series of Limited-Edition Strains in ‘Joint Effort’ With Craft Growers
  

Live Conference Call and Audio Webcast
Tilray Brands will host a webcast to discuss these results today at 8:30 a.m. ET. Investors may join the live webcast available on the Investors section of the Company’s website at www.tilray.com. The webcast will also be archived after the call concludes.

About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time. Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life, enhanced by moments of connection and wellbeing. Patients and consumers trust Tilray Brands to be the most responsible, trusted and market leading cannabis consumer products company in the world with a portfolio of innovative, high-quality and beloved brands that address the needs of the consumers, customers and patients we serve. A pioneer in cannabis research, cultivation, and distribution, Tilray Brands’ unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on Tilray Brands, visit www.Tilray.com and follow @Tilray

Cautionary Statement Concerning Forward-Looking Statements

Certain statements in this press release constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication.

Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the Company’s ability to become the world's leading cannabis-focused consumer branded company; the Company’s ability to achieve annualized cost savings of $130 million; the Company’s ability to generate $70-$80 million of Adjusted EBITDA; the Company’s expectation to be free-cash flow positive in its operating business units; the Company’s ability to achieve long term profitability; the Company’s ability to achieve operational scale, market share, distribution, profitability and revenue growth in particular business lines and markets; the Company’s ability to successfully achieve production and supply chain efficiencies, synergies and cost savings; expansion of medical and recreational sales legalization across the global cannabis industry, including in Europe; and the Company’s anticipated investments and acquisitions, including in organic and strategic growth, partnership efforts, product offerings and other initiatives.

Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of the Company and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of the Company made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Use of Non-U.S. GAAP Financial Measures
This press release and the accompanying tables include non-GAAP financial measures, including adjusted gross margin, Adjusted gross profit, Adjusted EBITDA, Adjusted net income and free cash flow. Management believes that the non-GAAP financial measures presented provide useful additional information to investors about current trends in the Company's operations and are useful for period-over-period comparisons of operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read only in connection with the Company's Consolidated Statements of Operations and Cash Flows presented in accordance with GAAP.

Certain forward-looking non-GAAP financial measures included in this press release are not reconciled to the comparable forward-looking GAAP financial measures. The Company is not able to reconcile these forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures without unreasonable efforts because the Company is unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures but would not impact the non-GAAP measures. Such items may include litigation and related expenses, transaction costs, impairments, foreign exchange movements and other items. The unavailable information could have a significant impact on the Company's GAAP financial results.

The Company believes presenting net sales at constant currency provides useful information to investors because it provides transparency to underlying performance in the Company's consolidated net sales by excluding the effect that foreign currency exchange rate fluctuations have on period-to-period comparability given the volatility in foreign currency exchange markets. To present this information for historical periods, current period net sales for entities reporting in currencies other than the U.S. dollar are translated into U.S. dollars at the average monthly exchange rates in effect during the corresponding period of the prior fiscal year, rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year. As a result, the foreign currency impact is equal to the current year results in local currencies multiplied by the change in average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year.

Adjusted EBITDA is calculated as net income (loss) before income tax expense (recovery); interest expense, net; non-operating income (expense), net; amortization; stock-based compensation; change in fair value of contingent consideration; purchase price accounting step-up; facility start-up and closure costs; lease expense; litigation costs; and transaction costs. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Adjusted gross profit, is calculated as gross profit adjusted to exclude the impact of inventory valuation adjustment and purchase price accounting valuation step-up. A reconciliation of Adjusted gross profit, excluding inventory valuation adjustments and purchase price accounting valuation step-up, to gross profit, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Adjusted gross margin, excluding inventory valuation adjustments and purchase price accounting valuation step-up, is calculated as revenue less cost of sales adjusted to add back inventory valuation adjustments and amortization of inventory step-up, divided by revenue. A reconciliation of Adjusted gross margin, excluding inventory valuation adjustments and purchase price accounting valuation step-up, to gross margin, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Adjusted net income is calculated as net (loss) income plus (minus) non-operating income (expense), net, change in fair value of contingent consideration, inventory write down, litigation costs, and transaction (income) costs. A reconciliation of Adjusted net income, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Free cash flow is comprised of two GAAP measures deducted from each other which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets. A reconciliation of net cash flow provided by (used in) operating activities to free cash flow, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release.

For further information:

Media: Berrin Noorata, news@tilray.com
Investors: Raphael Gross, +1-203-682-8253, Raphael.Gross@icrinc.com

 

Consolidated Statements of Financial Position
		November 30,				May 31,
(in thousands of US dollars)			2022				2022
Assets
Current assets
Cash and cash equivalents		$	190,218			$	415,909
Marketable Securities			243,286				-
Accounts receivable, net			89,705				95,279
Inventory			240,946				245,529
Prepaids and other current assets			50,550				46,786
Total current assets			814,705				803,503
Capital assets			539,124				587,499
Right-of-use assets			11,351				12,996
Intangible assets			1,214,842				1,277,875
Goodwill			2,621,401				2,641,305
Interest in equity investees			4,638				4,952
Long-term investments			8,211				10,050
Convertible notes receivable			255,310				111,200
Other assets			4,797				314
Total assets		$	5,474,379			$	5,449,694
Liabilities
Current liabilities
Bank indebtedness		$	15,304			$	18,123
Accounts payable and accrued liabilities			162,900				157,431
Contingent consideration			26,463				16,007
Warrant liability			12,670				14,255
Current portion of lease liabilities			6,976				6,703
Current portion of long-term debt			20,681				67,823
Current portion of convertible debentures payable			181,511				-
Total current liabilities			426,505				280,342
Long - term liabilities
Lease liabilities			8,999				11,329
Long-term debt			152,150				117,879
Convertible debentures payable			223,295				401,949
Deferred tax liabilities			180,099				196,638
Other liabilities			185				191
Total liabilities			991,233				1,008,328
Commitments and contingencies (refer to Note 18)
Stockholders' equity
Common stock ($0.0001 par value; 990,000,000 shares authorized; 613,181,559 and 532,674,887 shares issued and outstanding, respectively)			61				53
Additional paid-in capital			5,697,466				5,382,367
Accumulated other comprehensive loss			(121,455	)			(20,764	)
Accumulated Deficit			(1,105,796	)			(962,851	)
Total Tilray Brands, Inc. stockholders' equity			4,470,276				4,398,805
Non-controlling interests			12,870				42,561
Total stockholders' equity			4,483,146				4,441,366
Total liabilities and stockholders' equity		$	5,474,379			$	5,449,694

Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)
		For the three months															For the six months
		ended November 30,								Change				% Change			ended November 30,								Change				% Change
(in thousands of U.S. dollars, except for per share data)			2022				2021			2022 vs. 2021								2022				2021			2022 vs. 2021
Net revenue		$	144,136			$	155,153			$	(11,017	)		(7	)%		$	297,347			$	323,176			$	(25,829	)		(8	)%
Cost of goods sold			104,012				122,387				(18,375	)		(15	)%			208,609				239,455				(30,846	)		(13	)%
Gross profit			40,124				32,766				7,358			22	%			88,738				83,721				5,017			6	%
Operating expenses:
General and administrative			41,672				33,469				8,203			25	%			82,180				82,956				(776	)		(1	)%
Selling			9,669				9,210				459			5	%			19,340				16,642				2,698			16	%
Amortization			23,995				29,016				(5,021	)		(17	)%			48,354				59,755				(11,401	)		(19	)%
Marketing and promotion			8,535				7,120				1,415			20	%			15,783				12,585				3,198			25	%
Research and development			165				515				(350	)		(68	)%			331				1,300				(969	)		(75	)%
Change in fair value of contingent consideration			—				845				(845	)		(100	)%			211				1,682				(1,471	)		(87	)%
Litigation costs			2,815				1,080				1,735			161	%			3,260				2,274				986			43	%
Transaction (income) costs			5,064				7,040				(1,976	)		(28	)%			(7,752	)			31,425				(39,177	)		(125	)%
Total operating expenses			91,915				88,295				3,620			4	%			161,707				208,619				(46,912	)		(22	)%
Operating loss			(51,791	)			(55,529	)			3,738			(7	)%			(72,969	)			(124,898	)			51,929			(42	)%
Interest expense, net			(3,107	)			(9,940	)			6,833			(69	)%			(7,520	)			(20,110	)			12,590			(63	)%
Non-operating income (expense), net			(18,450	)			65,595				(84,045	)		(128	)%			(51,442	)			115,292				(166,734	)		(145	)%
(Loss) income before income taxes			(73,348	)			126				(73,474	)		(58,313	)%			(131,931	)			(29,716	)			(102,215	)		344	%
Income taxes (benefit) expense			(11,713	)			(5,671	)			(6,042	)		107	%			(4,502	)			(909	)			(3,593	)		395	%
Net (loss) income		$	(61,635	)		$	5,797			$	(67,432	)		(1,163	)%			(127,429	)			(28,807	)			(98,622	)		342	%
Net loss per share - basic and diluted		$	(0.11	)		$	0.00			$	(0.11	)		(11,456	)%		$	(0.24	)		$	(0.09	)		$	(0.15	)		164	%

Condensed Consolidated Statements of Cash Flows
		For the six months
		ended November 30,								Change				% Change
(in thousands of US dollars)			2022				2021			2022 vs. 2021
Cash used in operating activities:
Net loss		$	(127,429	)		$	(28,807	)		$	(98,622	)		342	%
Adjustments for:
Deferred income tax recovery			(12,941	)			(11,228	)			(1,713	)		15	%
Unrealized foreign exchange loss			2,261				(6,530	)			8,791			(135	)%
Amortization			67,387				76,804				(9,417	)		(12	)%
Loss on sale of capital assets			2,208				230				1,978			860	%
Inventory valuation write down			-				12,000				(12,000	)		(100	)%
Other non-cash items			8,177				3,739				4,438			119	%
Stock-based compensation			20,136				17,670				2,466			14	%
Loss on long-term investments & equity investments			1,918				2,197				(279	)		(13	)%
Loss (gain) on derivative instruments			18,997				(133,436	)			152,433			(114	)%
Change in fair value of contingent consideration			211				1,682				(1,471	)		(87	)%
Change in non-cash working capital:
Accounts receivable			6,690				2,734				3,956			145	%
Prepaids and other current assets			(7,780	)			(6,299	)			(1,481	)		24	%
Inventory			5,046				3,409				1,637			48	%
Accounts payable and accrued liabilities			(1,941	)			(44,513	)			42,572			(96	)%
Net cash used in operating activities			(17,060	)			(110,348	)			93,288			(85	)%
Cash used in investing activities:
Investment in capital and intangible assets			(7,537	)			(23,856	)			16,319			(68	)%
Proceeds from disposal of capital and intangible assets			2,160				8,264				(6,104	)		(74	)%
Purchase of marketable securities			(243,186	)			-				(243,186	)		0	%
Net cash paid for business acquisition			(24,372	)			-				(24,372	)		0	%
Net cash used in investing activities			(272,935	)			(15,592	)			(257,343	)		1650	%
Cash provided by (used in) financing activities:
Share capital issued, net of cash issuance costs			129,593				-				129,593			0	%
Shares effectively repurchased for employee withholding tax			(1,189	)			(3,927	)			2,738			(70	)%
Proceeds from long-term debt			1,288				-				1,288			0	%
Repayment of long-term debt and convertible debt			(59,395	)			(20,779	)			(38,616	)		186	%
Repayment of lease liabilities			(1,114	)			(3,360	)			2,246			(67	)%
Net (decrease) increase in bank indebtedness			(2,819	)			19				(2,838	)		(14937	)%
Net cash provided by (used in) financing activities			66,364				(28,047	)			94,411			(337	)%
Effect of foreign exchange on cash and cash equivalents			(2,060	)			(2,696	)			636			(24	)%
Net increase (decrease) in cash and cash equivalents			(225,691	)			(156,683	)			(69,008	)		44	%
Cash and cash equivalents, beginning of period			415,909				488,466				(72,557	)		(15	)%
Cash and cash equivalents, end of period		$	190,218			$	331,783			$	(141,565	)		(43	)%

Net Revenue by Operating Segment
		For the three months				% of Total Revenue			For the three months				% of Total Revenue			For the six months				% of Total Revenue			For the six months				% of Total Revenue
(In thousands of U.S. dollars)		November 30, 2022							November 30, 2021							November 30, 2022							November 30, 2021
Cannabis business		$	49,898			34	%		$	58,775			38	%		$	108,468			36	%		$	129,224			40	%
Distribution business			60,188			42	%			68,869			44	%			120,773			41	%			136,055			42	%
Beverage alcohol business			21,395			15	%			13,707			9	%			42,049			14	%			29,168			9	%
Wellness business			12,655			9	%			13,802			9	%			26,057			9	%			28,729			9	%
Total net revenue		$	144,136			100	%		$	155,153			100	%		$	297,347			100	%		$	323,176			100	%
Net Revenue by Operating Segment in Constant Currency
		For the three months							For the three months							For the six months							For the six months
		November 30, 2022							November 30, 2021							November 30, 2022							November 30, 2021
(In thousands of U.S. dollars)		as reported in constant currency				% of Total Revenue			as reported in constant currency				% of Total Revenue			as reported in constant currency				% of Total Revenue			as reported in constant currency				% of Total Revenue
Cannabis business		$	52,160			33	%		$	58,775			38	%		$	113,739			35	%		$	129,224			40	%
Distribution business			70,952			45	%			68,869			44	%			141,532			44	%			136,055			42	%
Beverage alcohol business			21,395			14	%			13,707			9	%			42,049			13	%			29,168			9	%
Wellness business			13,074			8	%			13,802			9	%			26,759			8	%			28,729			9	%
Total net revenue		$	157,581			100	%		$	155,153			100	%		$	324,079			100	%		$	323,176			100	%
Net Cannabis Revenue by Market Channel
		For the three months				% of Total Revenue			For the three months				% of Total Revenue			For the six months				% of Total Revenue			For the six months				% of Total Revenue
(In thousands of U.S. dollars)		November 30, 2022							November 30, 2021							November 30, 2022							November 30, 2021
Revenue from Canadian medical cannabis products		$	6,365			13	%		$	7,929			13	%		$	12,885			12	%		$	16,303			13	%
Revenue from Canadian adult-use cannabis products			52,390			106	%			49,535			85	%			110,745			101	%			119,128			91	%
Revenue from wholesale cannabis products			236			0	%			2,259			4	%			628			1	%			3,959			3	%
Revenue from international cannabis products			7,705			15	%			13,706			23	%			18,127			17	%			23,972			19	%
Less excise taxes			(16,798	)		-34	%			(14,654	)		-25	%			(33,917	)		-31	%			(34,138	)		-26	%
Total		$	49,898			100	%		$	58,775			100	%		$	108,468			100	%		$	129,224			100	%
Net Cannabis Revenue by Market Channel in Constant Currency
		For the three months							For the three months							For the six months							For the six months
		November 30, 2022							November 30, 2021							November 30, 2022							November 30, 2021
(In thousands of U.S. dollars)		as reported in constant currency				% of Total Revenue			as reported in constant currency				% of Total Revenue			as reported in constant currency				% of Total Revenue			as reported in constant currency				% of Total Revenue
Revenue from Canadian medical cannabis products		$	6,820			13	%		$	7,929			13	%		$	13,651			12	%		$	16,303			13	%
Revenue from Canadian adult-use cannabis products			53,635			103	%			49,535			85	%			114,056			100	%			119,128			91	%
Revenue from wholesale cannabis products			252			0	%			2,259			4	%			664			1	%			3,959			3	%
Revenue from international cannabis products			9,489			18	%			13,706			23	%			21,358			19	%			23,972			19	%
Less excise taxes			(18,036	)		-35	%			(14,654	)		-25	%			(35,990	)		-32	%			(34,138	)		-26	%
Total		$	52,160			100	%		$	58,775			100	%		$	113,739			100	%		$	129,224			100	%

Other Financial Information: Key Operating Metrics
		For the three months								For the six months
		ended November 30,								ended November 30,
(in thousands of U.S. dollars)			2022				2021				2022				2021
Net cannabis revenue		$	49,898			$	58,775			$	108,468			$	129,224
Distribution revenue			60,188				68,869				120,773				136,055
Net beverage alcohol revenue			21,395				13,707				42,049				29,168
Wellness revenue			12,655				13,802				26,057				28,729
Cannabis costs			31,335				45,259				60,196				85,450
Beverage alcohol costs			11,420				5,921				22,269				12,583
Distribution costs			52,495				61,237				107,479				120,527
Wellness costs			8,762				9,970				18,665				20,895
Adjusted gross profit (excluding PPA step-up and inventory valuation adjustments) (1)			41,231				44,766				90,952				95,721
Cannabis adjusted gross margin (excluding inventory valuation adjustments) (1)			37	%			43	%			45	%			43	%
Beverage alcohol adjusted gross margin (excluding PPA step-up) (1)			52	%			57	%			52	%			57	%
Distribution gross margin			13	%			11	%			11	%			11	%
Wellness gross margin			31	%			28	%			28	%			27	%
Adjusted EBITDA (1)			11,708				13,760				25,239				26,457
Cash and cash equivalents and marketable securities			433,504				331,783				433,504				331,783
Working capital			388,200				393,350				388,200				393,350

Other Financial Information: Gross Margin and Adjusted Gross Margin
		For the three months ended November 30, 2022
(In thousands of U.S. dollars)		Cannabis				Beverage				Distribution				Wellness				Total
Net revenue		$	49,898			$	21,395			$	60,188			$	12,655			$	144,136
Cost of goods sold			31,335				11,420				52,495				8,762				104,012
Gross profit			18,563				9,975				7,693				3,893				40,124
Gross margin			37	%			47	%			13	%			31	%			28	%
Adjustments:
Purchase price accounting step-up			-				1,107				-				-				1,107
Adjusted gross profit			18,563				11,082				7,693				3,893				41,231
Adjusted gross margin			37	%			52	%			13	%			31	%			29	%
		For the three months ended November 30, 2021
(In thousands of U.S. dollars)		Cannabis				Beverage				Distribution				Wellness				Total
Net revenue		$	58,775			$	13,707			$	68,869			$	13,802			$	155,153
Cost of goods sold			45,259				5,921				61,237				9,970				122,387
Gross profit			13,516				7,786				7,632				3,832				32,766
Gross margin			23	%			57	%			11	%			28	%			21	%
Adjustments:
Inventory valuation adjustments			12,000				-				-				-				12,000
Purchase price accounting step-up			-				-				-				-				-
Adjusted gross profit			25,516				7,786				7,632				3,832				44,766
Adjusted gross margin			43	%			57	%			11	%			28	%			29	%
		For the six months ended November 30, 2022
(In thousands of U.S. dollars)		Cannabis				Beverage				Distribution				Wellness				Total
Net revenue		$	108,468			$	42,049			$	120,773			$	26,057			$	297,347
Cost of goods sold			60,196				22,269				107,479				18,665				208,609
Gross profit			48,272				19,780				13,294				7,392				88,738
Gross margin			45	%			47	%			11	%			28	%			30	%
Adjustments:
Purchase price accounting step-up			-				2,214				-				-				2,214
Adjusted gross profit			48,272				21,994				13,294				7,392				90,952
Adjusted gross margin			45	%			52	%			11	%			28	%			31	%
		For the six months ended November 30, 2021
(In thousands of U.S. dollars)		Cannabis				Beverage				Distribution				Wellness				Total
Net revenue		$	129,224			$	29,168			$	136,055			$	28,729			$	323,176
Cost of goods sold			85,450				12,583				120,527				20,895				239,455
Gross profit			43,774				16,585				15,528				7,834				83,721
Gross margin			34	%			57	%			11	%			27	%			26	%
Adjustments:
Inventory valuation adjustments			12,000				-				-				-				12,000
Adjusted gross profit			55,774				16,585				15,528				7,834				95,721
Adjusted gross margin			43	%			57	%			11	%			27	%			30	%

Other Financial Information: Adjusted Earnings Before Interest, Taxes and Amortization
		For the three months															For the six months
		ended November 30,								Change				% Change			ended November 30,								Change				% Change
(In thousands of U.S. dollars)			2022				2021			2022 vs. 2021								2022				2021			2022 vs. 2021
Net (loss) income		$	(61,635	)		$	5,797			$	(67,432	)		(1,163	)%		$	(127,429	)		$	(28,807	)		$	(98,622	)		342	%
Income taxes (benefit) expense			(11,713	)			(5,671	)			(6,042	)		107	%			(4,502	)			(909	)			(3,593	)		395	%
Interest expense, net			3,107				9,940				(6,833	)		(69	)%			7,520				20,110				(12,590	)		(63	)%
Non-operating income (expense), net			18,450				(65,595	)			84,045			(128	)%			51,442				(115,292	)			166,734			(145	)%
Amortization			33,318				37,471				(4,153	)		(11	)%			67,387				76,804				(9,417	)		(12	)%
Stock-based compensation			10,943				8,253				2,690			33	%			20,136				17,670				2,466			14	%
Change in fair value of contingent consideration			-				845				(845	)		(100	)%			211				1,682				(1,471	)		(87	)%
Purchase price accounting step-up			1,107				-				1,107			NM				2,214				-				2,214			NM
Facility start-up costs			3,000				1,700				1,300			76	%			4,800				2,900				1,900			66	%
Facility closure and exit costs			6,552				-				6,552			NM				6,552				5,000				1,552			31	%
Lease expense			700				900				(200	)		(22	)%			1,400				1,600				(200	)		(13	)%
Litigation costs			2,815				1,080				1,735			161	%			3,260				2,274				986			43	%
Inventory write down			-				12,000				(12,000	)		(100	)%			-				12,000				(12,000	)		(100	)%
Transaction (income) costs			5,064				7,040				(1,976	)		(28	)%			(7,752	)			31,425				(39,177	)		(125	)%
Adjusted EBITDA		$	11,708			$	13,760			$	(2,052	)		(15	)%		$	25,239			$	26,457			$	(1,218	)		(5	)%
Other Financial Information: Adjusted Net Loss
		For the three months															For the six months
		ended November 30,								Change				% Change			ended November 30,								Change				% Change
(In thousands of U.S. dollars)			2022				2021			2022 vs. 2021								2022				2021			2022 vs. 2021
Net (loss) income		$	(61,635	)		$	5,797			$	(67,432	)		(1,163	)%		$	(127,429	)		$	(28,807	)		$	(98,622	)		342	%
Non-operating income (expense), net			18,450				(65,595	)			84,045			(128	)%			51,442				(115,292	)			166,734			(145	)%
Change in fair value of contingent consideration			-				845				(845	)		(100	)%			211				1,682				(1,471	)		(87	)%
Inventory write down			-				12,000				(12,000	)		(100	)%			-				12,000				(12,000	)		(100	)%
Litigation costs			2,815				1,080				1,735			161	%			3,260				2,274				986			43	%
Transaction (income) costs			5,064				7,040				(1,976	)		(28	)%			(7,752	)			31,425				(39,177	)		(125	)%
Adjusted net loss		$	(35,306	)		$	(38,833	)		$	3,527			(9	)%		$	(80,268	)		$	(96,718	)		$	16,450			(17	)%
Adjusted net loss per share - basic and diluted		$	(0.06	)		$	(0.08	)		$	0.03			(32	)%		$	(0.14	)		$	(0.21	)		$	0.08			(36	)%
Other Financial Information: Free Cash Flow
		For the three months															For the six months
		ended November 30,								Change				% Change			ended November 30,								Change				% Change
(In thousands of U.S. dollars)			2022				2021			2022 vs. 2021								2022				2021			2022 vs. 2021
Net cash provided by (used in) operating activities		$	29,209			$	(17,121	)		$	46,330			(0,271	)%		$	(17,060	)		$	(110,348	)		$	93,288			-85	%
Less: investments in capital and intangible assets, net			(3,840	)			(6,972	)			3,132			(45	)%			(5,377	)			(15,592	)			10,215			(66	)%
Free cash flow		$	25,369			$	(24,093	)		$	49,462			(205	)%		$	(22,437	)		$	(125,940	)		$	103,503			(82	)%

FAQ

What were Tilray's financial results for Q2 2022?

Tilray reported a net revenue of $144.1 million for Q2 2022, with a free cash flow of $25.4 million.

How much operating cash flow did Tilray achieve in Q2 2022?

Tilray achieved an operating cash flow of $29.2 million in Q2 2022.

What is the adjusted EBITDA reported by Tilray?

Tilray reported an adjusted EBITDA of $11.7 million for the 15th consecutive quarter.

What acquisition did Tilray complete recently?

Tilray completed the acquisition of Montauk Brewing Company, the #1 craft beer in Metro New York.

What is Tilray's market share in Canada?

Tilray maintained a market share of 8.3% in the Canadian cannabis market.